New strategies to enhance photodynamic therapy for solid tumors
Broekgaarden, M.

Citation for published version (APA):
Broekgaarden, M. (2016). New strategies to enhance photodynamic therapy for solid tumors
Chapter 9

Inhibition of hypoxia-inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinoma cells to photodynamic therapy

Ruud Weijer\textsuperscript{1a}, Mans Broekgaarden\textsuperscript{1a}, Massis Krekorian\textsuperscript{1}, Lindy K. Alles\textsuperscript{1}, Albert C. van Wijk\textsuperscript{1}, Claire Mackaaij\textsuperscript{2}, Joanne Verheij\textsuperscript{2}, Allard C. van der Wal\textsuperscript{2}, Thomas M. van Gulik\textsuperscript{1}, Gert Storm\textsuperscript{2,3}, Michal Heger\textsuperscript{1,3}

\textsuperscript{1} Department of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
\textsuperscript{2} Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
\textsuperscript{3} Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Utrecht, the Netherlands
\textsuperscript{a} equal contributions

This chapter has been accepted for publication in: Oncotarget 2015.

Abstract

Photodynamic therapy (PDT) induces tumor cell death by oxidative stress and hypoxia but also survival signaling through activation of hypoxia-inducible factor 1 (HIF-1). Since perihilar cholangiocarcinomas are relatively recalcitrant to PDT, the aims were to (1) determine the expression levels of HIF-1-associated proteins in human perihilar cholangiocarcinomas, (2) investigate the role of HIF-1 in PDT-treated human perihilar cholangiocarcinoma cells, and (3) determine whether HIF-1 inhibition reduces survival signaling and enhances PDT efficacy.

The expression of VEGF, CD105, CD31/Ki-67, and GLUT-1 was determined by immunohistochemistry in human perihilar cholangiocarcinomas. In addition, the behavior of human perihilar cholangiocarcinoma (Sk-Cha1) cells towards PDT with liposome-delivered zinc phthalocyanine was investigated under both normoxic and hypoxic conditions. Acriflavine, a HIF-1\textalpha/HIF-1\textbeta dimerization inhibitor and a potential dual topoisomerase I/II inhibitor, was evaluated for its adjuvant effect on PDT efficacy. Increased expression of VEGF, CD105, CD31/Ki-67, and GLUT-1 was confirmed in human perihilar cholangiocarcinomas. PDT with liposome-delivered zinc phthalocyanine caused HIF-1\textalpha stabilization in Sk-Cha1 cells and increased transcription of HIF-1\textalpha downstream genes. Acriflavine was taken up by Sk-Cha1 cells and co-translocated to the nucleus under hypoxic conditions. Importantly, pretreatment of Sk-Cha1 cells with acriflavine enhanced PDT efficacy via inhibition of HIF-1 and topoisomerases I and II.

HIF-1, which is activated in human hilar cholangiocarcinomas, contributes to tumor cell survival following PDT in vitro. Combining PDT with acriflavine pretreatment improves PDT efficacy in cultured cells and therefore warrants further preclinical validation for therapy-recalcitrant perihilar cholangiocarcinomas.

1. Introduction

Photodynamic therapy (PDT) is a non-to-minimally invasive treatment modality for a vari-
ety of solid cancers. This therapy is based on the accumulation of a light-sensitive drug (photosensitizer) in the tumor following systemic administration. Next, the photosensitizer-replete tumor is locally irradiated with (laser)light, resulting in the activation of the photosensitizer and subsequent production of reactive oxygen species (ROS) via type I (superoxide) and type II (singlet oxygen) photochemical reactions. Consequently, PDT locally induces a state of hyperoxidative stress, culminating in tumor cell death, destruction of the microvasculature that causes tumor hypoxia and hyponutrition, and an anti-tumor immune response.\(^1,2\)

PDT is effective in the curative treatment of (pre-)malignant skin lesions (actinic keratosis, basal/squamous cell carcinoma)\(^3\), but is also employed as (last-line) treatment of head and neck cancer\(^4\), early central stage lung tumors\(^5\), esophageal cancer\(^6\), nasopharyngeal carcinomas\(^7\), bladder cancer\(^8\), and non-resectable perihilar cholangiocarcinomas\(^9\). Although PDT yields complete response rates of 50-90% in the majority of the abovementioned cancers, nasopharyngeal-, urothelial-, and perihilar cholangiocarcinomas are relatively refractory to PDT. This may be in part due to hypoxia-mediated survival signaling that is triggered by the stabilization of hypoxia inducible factor 1 (HIF-1) following PDT\(^10\)-12. In nasopharyngeal and superficial urothelial carcinomas, the overexpression of HIF-1\(\alpha\) has been associated with poor overall survival\(^13,14\). HIF-1 expression levels in perihilar cholangiocarcinomas are currently elusive but may account for the recalcitrance of these tumors to therapy\(^15\).

HIF-1 is a transcription factor composed of HIF-1\(\alpha\) and HIF-1\(\beta\) subunits. During normoxia, prolyl-hydroxylases (PHD) and factor inhibiting HIF (FIH) mediate the hydroxylation of Pro402, Pro564, and/or Asn803 of HIF-1\(\alpha\)\(^16\). In turn, Von Hippel-Lindau tumor suppressor protein (VHL) binds to hydroxylated HIF-1\(\alpha\), resulting in complexation with E3 ubiquitin ligase and subsequent proteasomal degradation of HIF-1\(\alpha\)\(^17,18\). In contrast, hypoxia inhibits the activity of both PHDs and FIH, leading to HIF-1\(\alpha\) stabilization and nuclear translocation\(^19\). After translocation to the nucleus, HIF-1\(\alpha\) dimerizes with HIF-1\(\beta\) and mediates the transcription of various genes\(^20\) that are involved in glycolysis, angiogenesis, survival, and apoptosis\(^21\)-23. Alternatively, HIF-1 may also be activated through ROS, which also deter the activity of PHDs and FIH, leading to the stabilization and nuclear translocation of HIF-1\(\alpha\)\(^24,25\). HIF-1 is constitutively active in most tumors since the tumor growth rate exceeds the rate of neoangiogenesis\(^21,23\). Moreover, HIF-1 is responsible for resistance to chemotherapy and radiotherapy\(^26,27\). PDT increases HIF-1 activity in mouse mammary carcinoma (EMT-6) cells\(^28\) and human bladder cancer (UROtsa, RT112, and J84 but not RT4) cells\(^29\) as well as in murine Kaposi’s sarcoma\(^30\), BA mouse mammary carcinoma\(^31,32\), and CNE2 nasopharyngeal carcinoma xenografts\(^33\). Inhibition of HIF-1 activity and corollary survival signaling may therefore improve the therapeutic efficacy of PDT.

This study therefore investigated the therapeutic potential of the HIF-1 dimerization inhibitor acriflavine (ACF) in an in vitro PDT setting. Moreover, ACF was also investigated in the context of its dual topoisomerase I and II inhibitor activity\(^34\). Topoisomerases are involved in the cleavage and resealing of DNA breaks during transcription and cell replication, and inhibition of these topoisomerases may lead to cell cycle arrest and apoptosis in dividing cells (reviewed in\(^35\)).

The most important findings were that HIF-1 is activated by sublethal PDT in human perihilar cholangiocarcinoma (Sk-Cha1) cells\(^36\), i.e., a cell line derived from a type of cancer that is recalcitrant to different types of treatment. Immunostaining of patient-derived perihilar cholangiocarcinoma biopsies demonstrated extensive neovascularization in desmoplastic tissue and heterogeneous glucose transporter 1 (GLUT-1) overexpression, hinting towards the possible involvement of hypoxia- and HIF-1-mediated angiogenesis. In vitro, HIF-1-mediated tumor cell survival after PDT with liposomal-delivered zinc phthalocyanine (ZnPc, photosensitizer) was associated with transcriptional upregulation of HIF-1-regulated prostaglandin-endoperoxide synthase 2 (PTGS2) and heme oxygenase 1 (HMOX-1), both involved in survival, and serpin peptidase inhibitor, clade E (SERPINE1), which is involved in angiogenesis. Pretreatment of tumor cells with ACF improved PDT outcome and reduced the PDT-induced expression of vascular endothelial growth factor (VEGF) and PTGS2. Confocal microscopy experiments showed that ACF exhibits an intracellular localization pattern that is similar to that of HIF-1\(\alpha\). Lastly, incubation of Sk-Cha1 cells with ACF resulted in induction of S-phase cell cycle
arrest, DNA damage, and apoptosis, altogether underscoring ACF’s dual topoisomerase I/II inhibitor potential and utility to act as a neoadjuvant chemotherapeutic in PDT.

2. Materials and Methods

2.1 Chemicals

1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine (DPPS), and 3β-[N-(N',N'-dimethylaminoethane)-carbimoyl]cholesterol (DC-chol) were purchased from Avanti Polar Lipids (Alabaster, AL). L-α-phosphatidylethanolamine, distearoyl methoxypolyethylene glycol conjugate (DSPE-PEG, average PEG molecular mass of 2,000 amu), ZnPC, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), fibronectin, sodium chloride (NaCl), β-mercaptoethanol, cholesterol, chloroform, Nile Red, paraformaldehyde, sucrose, bovine serum albumin (BSA), Tween 20, CoCl₂, ACF, and pyridine were obtained from Sigma-Aldrich (St. Louis, MO). Tris-HCl and dimethyl sulfoxide (DMSO) were purchased from Merck KgaA (Darmstadt, Germany). Ethanol was obtained from Biosolve (Valkenswaard, the Netherlands). Protease inhibitor cocktail and water-soluble tetrazolium-1 (WST-1) were purchased from Roche Applied Science (Basel, Switzerland). 2',7'-dichlorodihydrofluorescein diacetate (DCFH₂-DA) was obtained from Life Technologies (Carlsbad, CA).

All lipids were dissolved in chloroform, purged with nitrogen gas, and stored at -20 °C. Phospholipid stock concentrations were determined by the inorganic phosphate assay modified from 37. ZnPC was dissolved in pyridine at a 178-μM concentration and stored at room temperature (RT) in the dark, CoCl₂ was dissolved in MilliQ at a concentration of 50 mM, and ACF and DCFH₂-DA were dissolved in DMSO at a concentration of 50 mM.

2.2 Histology

Histology was performed on two patient-derived, paraffin-embedded perihilar cholangiocarcinoma tissues. Tissue sections were dewaxed in xylene and rehydrated in graded steps of ethanol. Endogenous peroxidase activity was blocked with methanol containing 0.3% peroxide (20 min, RT). Heat-induced epitope retrieval (HIER) was performed in a pretreatment module (Thermo Fisher Scientific, Fremont, CA) using Tris-EDTA (VEGF, Ki-67, CD31, GLUT-1) or citrate buffer (CD105) for 20 minutes at 98 °C. Throughout the staining procedure all washing steps were performed with Tris-buffered saline. Superblock (Immunologic, Duiven, the Netherlands) was applied as a protein block prior to staining with primary antibodies.

All antibodies were diluted with antibody diluent (Scytek, Logan, UT). Single stains for CD105 (rabbit anti-human, polyclonal, cat # RB-9291, Thermo Fischer Scientific), VEGF (rabbit anti-human, polyclonal, cat. # sc-152, Santa Cruz Biotechnology, Santa Cruz, CA), and GLUT-1 (rabbit anti-human, polyclonal, cat. # RB-9052, Thermo Fischer Scientific) were performed. These primary antibodies were visualized with BrightVision HRP-conjugated anti-rabbit polymer (Immunologic) and BrightDAB. The sections were counterstained with hematoxylin.

Sequential double staining 38 was performed for CD31 (mouse anti-human, clone JC70A, cat. # M0823, Dako, Glostrup, Denmark) and Ki-67 (rabbit anti-human, clone SP6, cat. # RM9106, Thermo Fisher Scientific). Ki-67 was visualized with BrightVision AP-conjugated anti-rabbit polymer (Immunologic) and Vector Red (Vector Labs, Burlingame, CA). Next, an intermediate HIER step using Tris-EDTA buffer (10 minutes at 98 °C) was applied to remove all antibodies but leaving the chromogen intact 39. Finally, CD31 was visualized with BrightVision AP-conjugated anti-mouse polymer (Immunologic) and PermaBlue plus/AP (Diagnostics Biosystems, Pleasanton, CA). All slides were dried on a hotplate (50 °C) and permanently mounted with Vectamount (Vector Labs).

It should be noted that, as part of the clinical diagnostics protocol at the Department of Pathology, all antibodies had been validated for their cross-reactivity and immunohistological staining efficacy using tissue that overexpresses the respective marker. Immunostaining for HIF-1α directly
was not performed due to the instability of the HIF-1α antigen (degrades within a few minutes after biopsy).

2.3 Liposome preparation

ZnPC-ETLs were composed of DPPC:DC-chol:cholesterol:DSPE-PEG (66:25:5:4, molar ratio) and ZnPC was incorporated at a ZnPC:lipid molar ratio of 0.003. Liposomes were prepared using the lipid film hydration technique as described previously. ZnPC-ETLs were characterized for size and polydispersity by photon correlation spectroscopy (Zetasizer 3000, Malvern Instruments, Malvern, Worcestershire, UK). Liposomes were purged with nitrogen and stored in the dark at 4 °C until use.

2.4 Cell culture

Human perihilar cholangiocarcinoma (Sk-Cha1) cells were grown at standard culture conditions (37 °C, 5% CO₂, and 95% air) and cultured in Roswell Park Memorial Institute (RPMI) 1640 culture medium supplemented with 10% fetal bovine serum (FBS) (v/v) (both from Gibco, Invitrogen, Carlsbad, CA), 1% penicillin/streptomycin (v/v), 1% L-glutamine (v/v) (both from Lonza, Walkersville, MD), and 1×10⁻⁵% β-mercaptoethanol (v/v) (Sigma-Aldrich). Cells were passaged weekly at a 1:10 ratio.

2.5 PDT protocol

Cells were seeded in either 24-wells or 6-wells plates as indicated in the specific subsections and cultured until confluence. In case of ACF pre-treatment, cells were incubated with 3 μM ACF (in serum-free supplemented RPMI 1640 medium) for 24 hours prior to PDT. Next, cells were washed with PBS and incubated with ZnPC-ETLs (in serum-free supplemented RPMI 1640 medium) for 1 hour at standard culture conditions. Cells were washed twice with PBS and fresh serum- and phenol red-free supplemented RPMI 1640 was added to the cells. PDT was performed with a 671-nm solid state diode laser (CNI Laser, Changchun, China) at a power of 500 mW to achieve a cumulative radiant exposure of 15 J/cm². After PDT, cells were either placed at standard culture conditions (normoxia) or placed in a hypoxic chamber (hypoxia) to mimic vascular shutdown.

2.6 Cell viability

Cell viability was assessed using the WST-1 assay as described previously.

2.7 Western Blotting

Cells were seeded in 6-wells plates and cultured until confluence. Cells were incubated with 10 μM ZnPC-ETLs (final lipid concentration) and treated with PDT. At 0, 30, 60, 120, and 240 minutes after PDT, cells were placed on ice and lysed in ice-cold Laemmli buffer supplemented with protease inhibitor cocktail (1 tablet per 5 mL buffer). A 20-hour incubation with 500 μM CoCl₂ served as a positive control for HIF-1α stabilization. The lysates were passed 10 × through a 25-gauge needle (BD Biosciences, San Jose, CA) to shear DNA. Next, samples were placed in a heat block for 10 minutes at 95 °C after which the samples were centrifuged for 15 minutes at 13,000 × g (4 °C). Samples (30 μg) were loaded on a 10% SDS-PAGE precast gel (50 μL slot volume, Bio-Rad Laboratories, Hercules, CA) and the electrophoresis was performed for 90 minutes at 125 V. The gels were blotted onto methanol-primed PVDF membranes (Millipore, Billerica, MA) for 1 hour at 330 V at 4 °C. Protein membranes were blocked for 1 hour with 5% dried milk powder (Protifar, Nutricia, Cuijk, the Netherlands) in 0.2% Tween 20 Tris-buffered saline (TBST, 20 mM Tris-HCl, 150 mM NaCl, pH = 7.5). The membranes were incubated overnight at 4 °C on a rocker with anti-HIF-1α (1:500, clone 54/HIF-1α, BD Transduction Laboratories (Franklin Lakes, NJ)) and anti-β-actin (1:4,000, AC-74, Sigma-Aldrich).
Next, the membranes were washed 4 times in TBST and incubated with HRP-conjugated goat-antimouse IgG1 (1:1,000, Dako Cytomation (Glostrup, Denmark)) for 1 hour at RT. Subsequently, membranes were washed 3 times with TBST and 2 times with TBS. The enhanced chemiluminescence (ECL) kit (Thermo Scientific) was used as substrate for β-actin and ECL plus (Thermo Scientific) was used as substrate for HIF-1α. Protein bands were visualized on an ImageQuant LAS 3000 luminometer (GE Healthcare, Little Chalfont, UK).

2.8 qRT-PCR

Cells were seeded in 6-wells plates and treated with PDT as described. RNA was extracted using TRIzol according to the manufacturer's protocol (Life Technologies). RNA was quantified and analyzed with a Nanodrop 2000 UV-VIS spectrophotometer (Thermo Scientific). cDNA synthesis and RT-qPCR reactions were performed according to 44. The primers that were used in this study are listed in Table 1. The data was analyzed using the LinRegPCR software in which relative starting concentrations of each cDNA template (N0) were calculated 45, after which the N0 values of the target genes were corrected for the respective N0 of the S18 rRNA. All S18 rRNA-corrected N0 values of each gene were compared to the average N0 of the untreated normoxic control samples. A log2 transformation was performed in order to obtain absolute fold-differences in expression levels of the genes of interest.

Table 1. Primer information for primer pairs used for qRT-PCR.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer sequence</th>
<th>Reverse primer sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIF1A</td>
<td>GGCGGAAGAGCAGACAGAAGACAAGAAG</td>
<td>CCAAGGAGTTGCTCACAAGCC</td>
</tr>
<tr>
<td>ANGPT1</td>
<td>GCCTCACAGCTGAACACCGAGA</td>
<td>CCAGCATGGTGACGGCAGTT</td>
</tr>
<tr>
<td>ANGPT2</td>
<td>CCCCTAGCTGACATGCTGTT</td>
<td>CGCGTCTGGTTTCGCAAAG</td>
</tr>
<tr>
<td>BCL2</td>
<td>TTTGTTGAACTGACGCGCCGCG</td>
<td>CAGCGCTGACGCTTTTCACA</td>
</tr>
<tr>
<td>BECN1</td>
<td>ATGGGAGGAGAAGCACCACATG</td>
<td>TGTTCTCTATGAGGCTGCTCA</td>
</tr>
<tr>
<td>BIRC5</td>
<td>AGGACACCCCGCATCTTAC</td>
<td>GGGCTCAACAGGCCTGTTTC</td>
</tr>
<tr>
<td>EDN1</td>
<td>GGGGCTGAAAGGCTGCTTGA</td>
<td>TGCGCTCAAGACGGCTGTTTC</td>
</tr>
<tr>
<td>HKI1</td>
<td>GCGGCTCTGCTGCTTTTAC</td>
<td>CATGATTCATCTGCACC</td>
</tr>
<tr>
<td>HMox1</td>
<td>AGGGATATCTTGGTGC</td>
<td>GGTGAGGATAAGGTTGCTC</td>
</tr>
<tr>
<td>HSPA5</td>
<td>GGCATCGACCTGGGACACC</td>
<td>TACCTCCAGCTGGGCCCAG</td>
</tr>
<tr>
<td>LDHA</td>
<td>GAGGCTCAGTACATGCTTCA</td>
<td>GCAAGGTCTAGTCGCCAGTCC</td>
</tr>
<tr>
<td>PDHA</td>
<td>GGCGGCGCGGCACTCAC</td>
<td>TTAGCAGGACATGCA</td>
</tr>
<tr>
<td>PGK1</td>
<td>CCGCTGTTGACCCGAACTAC</td>
<td>CGACGGATTGAATTTGTCCA</td>
</tr>
<tr>
<td>PKM2</td>
<td>GGGGTTGGAGGATGTTAT</td>
<td>ACGGGCTGGCTGCTTGT</td>
</tr>
<tr>
<td>PTO1/2</td>
<td>GCCCGGCGGGTACATTAAA</td>
<td>CCCCCAGGAACGTTGATAT</td>
</tr>
<tr>
<td>SERPINE1</td>
<td>ATGCCCTCCTTCTACGAGGCC</td>
<td>TTTACAGTGCTTGGAGCGT</td>
</tr>
<tr>
<td>VEGF</td>
<td>CCCACACCATCATACATTGACA</td>
<td>CTATTCTGCAGGCTCTG</td>
</tr>
<tr>
<td>RPS18</td>
<td>TTGGCAAACTGAAGGCTTGA</td>
<td>GGAAACCCCTGACCTTTCCTG</td>
</tr>
</tbody>
</table>

2.9 Confocal microscopy

Microscope cover slips (24 × 40 mm, VWR, Lutterworth, UK) were first coated with 5×10-4% (w/v) fibronectin in 0.9% NaCl (Fresenius Kabi, Bad Homburg, Germany) for 2 hours at 37 °C. Next, the fibronectin-containing solution was aspirated and cells were seeded and allowed to grow overnight. To determine the ACF subcellular localization, cells were either untreated or subjected to PDT as described in the section “PDT protocol”, and subsequently incubated with 3 µM ACF for 4 hours under normoxia and hypoxia as specified. Next, cells were washed with 1 mL of PBS and fixed with a mixture of 4% paraformaldehyde and 0.2% sucrose for 5 min. Cells were washed with 1 mL of PBS and stained with 1 µM Nile Red (in PBS) for 1 min. Cells were washed thrice with 1 mL PBS and mounted on microscope slides using Vectashield mounting medium (Vector Laboratories, Burlingame, CA). After 1 h, the slides were sealed with nail polish.

For the assessment of DNA damage, cells were fixed with a mixture of 4% paraformaldehyde and 0.2% sucrose for 5 min and permeabilized in 0.1% TX-100 (in PBS) for 5 min. Next, cells were washed with 1 mL of PBS and incubated for 16 hours with mouse anti-human phospho-H2AX-Al- exaFluor647 (Cell Signaling Technology, Danvers, MA) at a 1:100 dilution in 0.5% BSA and 0.15% glycine (in PBS, staining buffer) at 4 °C. Next, cells were washed thrice with staining buffer and mount-
ed on microscope slides using Vectashield mounting medium with 4',6-diamidino-2-phenylindole (DAPI) (Vector Laboratories). After 1 h, the slides were sealed with nail polish.

Cells were imaged on a Leica SP8 laser scanning confocal microscopy system (Leica Microsystems, Wetzlar, Germany). Fluorescence intensities were measured at $\lambda_{ex} = 405$ nm, $\lambda_{em} = 415-480$ nm for DAPI, $\lambda_{ex} = 470$ nm, $\lambda_{em} = 480-550$ nm for ACF, $\lambda_{ex} = 540$ nm, $\lambda_{em} = 550-650$ nm for Nile Red, and $\lambda_{ex} = 660$ nm, $\lambda_{em} = 670-750$ nm for phospho-H2AX. All experiments were performed using the same laser and microscope hardware settings.

### 2.10 ACF degradation

To evaluate the stability of ACF during PDT, 450 $\mu$L of ACF (80 $\mu$M) in serum-free and phenol red-free RPMI 1640 medium was added to 24-wells plates. Next, 50 $\mu$L of increasing concentrations of ZnPC-containing cell phantoms (85% DPPC, 10% DPPS, 5% cholesterol, molar ratio; ZnPC:lipid ratio of 0.003) in physiological buffer (10 mM HEPES, 0.88% (w/v) NaCl, pH = 7.4, 0.292 osmol/kg) was added to the wells. The baseline ACF fluorescence was read at $\lambda_{ex} = 460 \pm 40$ nm and $\lambda_{em} = 520 \pm 520$ nm using a BioTek Synergy HT multi-well plate reader (Winooski, VT). Subsequently, the cells were subjected to PDT (500 mW, 15 J/cm²) and ACF fluorescence was determined as a measure for ACF degradation. The data was normalized to control wells (n = 4 per group).

### 2.11 ACF uptake

Cells were cultured in 24-wells plates until confluence. Cells were washed with PBS and incubated with ACF in supplemented serum-free RPMI 1640 medium for 24 hours. After incubation, cells were washed with PBS and fresh supplemented serum-free RPMI 1640 medium was added to the wells. Next, ACF fluorescence, as a measure for uptake, was read at $\lambda_{ex} = 460 \pm 40$ nm and $\lambda_{em} = 520 \pm 520$ nm using a BioTek Synergy HT multi-well plate reader. Data was normalized to protein content per well (n = 4 per group) as determined with the SRB assay.

### 2.12 Caspase 3/7 activity

Cells were cultured in 24-wells plates and subjected to treatment as described above. Cells were incubated in 200 $\mu$L of serum- and phenol-red free medium and maintained at either normoxic or hypoxic conditions for 3.5 hours post-treatment. After treatment and normoxic/hypoxic incubation, 25 $\mu$L of Caspase-Glo assay reagent (Promega, Madison, WI) was added and cells were incubated for 30 minutes under the aforementioned conditions. Luminescence was read on a BioTek Synergy HT multiwell plate reader at 560 ± 20 nm and a signal integration time of 1 s. Data was obtained from n = 5 measurements and was corrected for background luminescence.

### 2.13 Lactate production

Cells were cultured in 24-wells plates until confluence and treated with ACF and PDT as indicated in the section “PDT protocol”. After 24 hours, extracellular lactate levels were determined using The Edge blood lactate analyzer (Apex Biotechnology, Hsinchu, Taiwan). Lactate concentrations were determined from a standard curve and corrected for the average protein content per group as determined with the bicinchoninic acid assay (Thermo Scientific).

### 2.14 Flow cytometry

For cell cycle analysis, cells were seeded in 6-wells plates and cultured until 70-80% confluence. Cells were incubated with ACF (in supplemented serum-free RPMI 1640 medium) for 24 or 48 hours, after which the cell cycle analysis was performed using flow cytometry according to 41. The mode of cell death following ACF incubation was analyzed by flow cytometry using APC-conjugated...
Annexin V (eBioscience, San Diego, CA) for apoptosis and TO-PRO-3 (Life Technologies) for necrosis. Cells were seeded in 6-wells plates and cultured until 70-80% confluence. Next, cells were incubated with ACF (in supplemented serum-free RPMI 1640 medium) for 24 or 48 hours. After incubation, the samples were prepared as described previously and assayed on a FACSCanto II (Becton Dickinson, Franklin Lakes, NJ). Ten thousand events were recorded in the gated region and data was analyzed using FlowJo software (Treestar, Ashland, OR).

2.15 Intracellular ROS assay

Cells were seeded in 24-wells plates and cultured until 70-80% confluence. Thereafter, cells were washed with PBS and incubated with ACF or vehicle (DMSO) in supplemented serum-free RPMI 1640 medium for 24 or 48 hours. After the indicated time points, the medium was removed, cells were washed with serum- and phenol red-free RPMI 1640 medium, and cells were incubated with 100 μM DCFH2-DA (in serum- and phenol red-free RPMI 1640 medium) for 1 hour at standard culture conditions. Next, cells were washed with serum- and phenol red-free RPMI 1640 medium, and fresh serum- and phenol red-free RPMI 1640 medium was added to the wells. Intracellular 2',7'-dichlorofluorescein (DCF) fluorescence, which is a measure for ROS production, was read on a BioTek Synergy HT multiplate reader at λex = 460 ± 40 nm and λem = 520 ± 520 nm. Data was obtained from n = 6 measurements and was corrected for ACF fluorescence, protein content using the SRB assay, and DCF fluorescence (basal metabolic rate) of control cells.

2.16 Statistical analysis

Data were analyzed in GraphPad Prism software (GraphPad Software, San Diego, CA). Data was analyzed for normality using a Kolmogorov-Smirnov test. Normally distributed data sets were analyzed with either a student’s t-test or a one-way ANOVA and subsequent Bonferroni post-hoc test. Non-Gaussian data were statistically analyzed using a Mann-Whitney U or Kruskal-Wallis test and a Dunn’s post-hoc test. All data are reported as mean ± standard deviation. In the figures, inter-group differences are indicated with (*) and differences between treated groups versus the untreated (CTRL) group are indicated with (#). Differences between normoxic and hypoxic data are, when relevant, indicated with ($). The level of significance is reflected by a single (p < 0.05), double (p < 0.01), triple (p < 0.005), or quadruple sign (p < 0.001).

3. Results

3.1 Expression of hypoxia-related proteins in human perihilar cholangiocarcinoma

Although the incidence of tumor hypoxia and the importance of HIF-1 expression in a large variety of tumors have been widely established, literature on this phenomenon in perihilar cholangiocarcinomas is scarce. Therefore, it was investigated whether hypoxia-related proteins (VEGF for angiogenic signaling, CD105 and CD31/Ki-67 for neovascularization, and GLUT-1 for glycolysis) were present in perihilar cholangiocarcinoma resection specimens. Representative differently stained serial images are presented in Fig. 1.

The hematoxylin and eosin staining (Fig. 1A) revealed that perihilar cholangiocarcinomas were characterized by clusters of tumor cells surrounded by relatively large areas of desmoplastic tissue (i.e., stroma). The tumor mass stained positively for VEGF (as did liver tissue), whereas VEGF staining was less prominent in the tumor stroma (Fig. 1B). Nevertheless, the tumor stroma was densely vascularized. The vasculature in the desmoplastic tissue was not of pre-existent nature, as the endothelium stained positively for CD105, a marker for angiogenic endothelium (Fig. 1C), and Ki-67, a marker of proliferation (Fig. 1D). Of note, the tumor mass was largely devoid of Ki-67-positive cells, indicating that the perihilar cholangiocarcinomas in our patient population were slowly proliferating tumors. GLUT-1 was largely absent in the tumor cell mass and stroma (Fig. 1E), albeit
several regions containing GLUT-1-expressing cell clusters were observed in other sections of the tumor (Fig. 1F). Accordingly, these results provide compelling evidence for the presence of hypoxia and HIF-1 activation in perihilar cholangiocarcinomas, which likely drive angiogenesis and regional upregulation of glycolysis. Moreover, the perihilar cholangiocarcinomas are replete with vasculature that serves as a conduit for the delivery of liposome-encapsulated photosensitizers.

### 3.2 HIF-1 is activated after PDT

To establish whether HIF-1 was activated by PDT, the optimal PDT dose was first determined in perihilar cholangiocarcinoma (Sk-Cha1) cells. Sk-Cha1 cells were incubated with increasing concentrations of ZnPC-encapsulating cationic liposomes (ZnPC-ETLs) and subsequently treated with PDT (500 mW, 15 J/cm²). These liposomes have been shown to selectively accumulate in tumor endothelium, which is expected to translate to vascular shutdown and exacerbated tumor hypoxia following PDT. Moreover, the ZnPC-ETLs are taken up by tumor cells, including Sk-Cha1 cells (manuscript in preparation). After PDT, the cells were either maintained under normoxic or hypoxic culture conditions to mimic the PDT-induced vascular shutdown. Cell viability was determined 24 hours after PDT using the WST-1 assay. Cells exhibited a ZnPC concentration-dependent decrease in cell viability following PDT, whereby the extent of cell death was exacerbated by hypoxia (Fig. 2A). Since the IC50 concentration in normoxic and hypoxic cells were approximately 10 and 5 μM ZnPC-ETLs (final lipid concentration), respectively, these concentrations were used in the rest of the experiments.

Next, the stabilization of HIF-1α and induction of HIF-1α transcriptional targets were investigated following PDT. As shown in Fig. 2B, normoxic Sk-Cha1 exhibited no notable HIF-1α expression.
Stimulation of cells with cobalt chloride, which is commonly used to induce hypoxic signaling \(^50, 51\) and was therefore used as positive control, caused extensive HIF-1α stabilization. Accordingly, Sk-Cha1 cells that were placed in a hypoxic chamber stabilized HIF-1α in a time-dependent manner, albeit less extensively than after cobalt chloride stimulation. HIF-1α stabilization was enhanced upon PDT. The HIF-1α stabilization was associated with upregulated transcription of several HIF-1 target genes, including \textit{VEGF} (angiogenesis), \textit{PTGS2} (survival), and \textit{HMOX1} (survival) (Fig. 2C). Sk-Cha1 cells also upregulated \textit{SERPINE1} (angiogenesis) and baculoviral inhibitor of apoptosis repeat-containing 5 (\textit{BIRC5}, survival) after PDT. It was therefore concluded that HIF-1α is upregulated in Sk-Cha1 cells following PDT and hypothesized that HIF-1-mediated transcriptional responses of hypoxic Sk-Cha1 cells proceed via \textit{VEGF}, \textit{PTGS2}, \textit{SERPINE1}, \textit{HMOX1}, and \textit{BIRC5}.

### 3.3 ACF is translocated to the nucleus upon hypoxia and/or PDT

Since PDT induced HIF-1 signaling in Sk-Cha1 cells, which may be responsible for the therapeutic recalcitrance in vivo, we investigated whether the HIF-1α/HIF-1β dimerization inhibitor ACF would enhance PDT efficacy. First, the intracellular localization of ACF was determined by confocal microscopy, whereby the intrinsic fluorescence of ACF (λ\text{ex} = 453 nm and λ\text{em} = 507 nm) in combination with (intra)cellular membrane staining (Fig. 3). Sk-Cha1 cells were incubated with ACF during normoxia, hypoxia, and/or after PDT to study the cytosolic-to-nuclear translocation of ACF during these processes.

As shown in Fig. 3A, ACF was localized in both the nucleus and cytosol under normoxic conditions. PDT treatment was accompanied by a translocation of ACF towards the nucleus under normoxic conditions, which was further characterized by altered cell morphology that entailed cell shrinkage and blebbing (Fig. 3B). Hypoxia (in the absence of PDT) triggered prominent translocation of ACF from the cytosol to the nucleus (Fig. 3C) that was characteristic of the stabilization and nuclear translocation pattern of HIF-1α in hypoxic cells \(^52, 53\). These data also indirectly support the PDT-induced activation of hypoxic signaling in Fig. 2B and C, given that ACF is known to bind to HIF-
1α and hence co-translocates to the nucleus upon HIF-1α stabilization. PDT-treated Sk-Cha1 cells that were placed in a hypoxic environment revealed a similar ACF distribution pattern as PDT-treated cells under normoxic conditions. ACF was mainly found in the nucleus in PDT-treated hypoxic cells, albeit at relatively lower levels compared to untreated hypoxic cells (Fig. 3D).

### 3.4 ACF potentiated PDT efficacy

For clinical application purposes, ACF should remain stable during the application of PDT and during conditions of oxidative stress in order to inhibit HIF-1 activation after PDT and the subsequent microvascular shutdown. A model system was therefore used to study the stability of ACF during PDT. ACF was dissolved in buffer solution and exposed to increasing amounts of cell phantoms (i.e., artificial cells) loaded with ZnPC, of which it was demonstrated that ROS is produced upon irradiation. As shown in Fig. 4A, the application of PDT only marginally affected ACF fluorescence, confirming that ACF remained stable during illumination and conditions of hyperoxidative stress.

To determine the most suitable concentration of ACF for the improvement of PDT efficacy,
the concentration-dependent uptake and toxicity of ACF were tested in Sk-Cha1 cells. ACF uptake followed a concentration-dependent linear pattern up to 5 μM ACF (Fig. 4B). The toxicity of ACF was determined during a 24-hour incubation period under either normoxic or hypoxic conditions (Fig. 4C). The IC50 concentration during normoxia and hypoxia, determined with the WST-1 assay, was 29 and 73 μM, respectively. Inasmuch as Sk-Cha1 cells exhibited a relative viability of ~90% at 3 μM ACF...
during normoxia, this concentration was used in the rest of the experiments. Next, Sk-Cha1 cells were incubated with ACF for 24 hours under normoxic conditions and treated with PDT (Fig. 4D) to investigate ACF’s adjuvant efficacy. As indicated, ACF was mildly toxic, which translated to slightly increased cytotoxicity when combined with PDT and normoxic incubation (Fig. 4D). A similar trend was observed in cells that were maintained under hypoxic conditions after PDT (Fig. 4E). In addition, the levels of caspase 3 and 7 (i.e., apoptosis markers) were assayed 4 hours post-treatment (Fig. 4F, G). Under normoxic conditions, neither ACF nor PDT significantly affected caspase 3/7 levels, however, ACF + PDT resulted in a 8-fold higher caspase 3/7 activity in Sk-Cha1 cells (Fig. 4G). During hypoxia, PDT resulted in a 4-fold increase in caspase 3/7 activity and ACF + PDT resulted in a 10-fold higher caspase 3/7 activity, indicating that apoptosis constitutes an important mode of cell death following combination treatment of ACF + PDT. None of the conditions induced the formation of DNA double-strand breaks, as assessed by a phospho-H2AX staining 4 hours after treatment (Fig. 4I-P), indicating that neither hypoxia nor ACF or PDT induce direct damage to DNA in the acute phase.

Lastly, inasmuch as HIF-1 signaling is a driving force behind glycolysis and the consequent

**Figure 5.** Gene expression analysis after control (CTRL), ACF, PDT, and ACF + PDT treatment. Gene expression levels were obtained by qRT-PCR from Sk-Cha1 cells as analyzed 0 hour, 2 hours, or 4 hours post-treatment under hypoxic conditions. The plotted heat map data represents the log2-transformed fold change of each data point in relation to the 0-hour normoxic CTRL. Upregulated genes are depicted in red, downregulated genes in green. Numeric data is presented in Table 2.

![Heat map of gene expression](image)

<table>
<thead>
<tr>
<th>Gene</th>
<th>CTRL 0h</th>
<th>ACF 0h</th>
<th>PDT 0h</th>
<th>ACF + PDT 0h</th>
<th>CTRL 2h</th>
<th>ACF 2h</th>
<th>PDT 2h</th>
<th>ACF + PDT 2h</th>
<th>CTRL 4h</th>
<th>ACF 4h</th>
<th>PDT 4h</th>
<th>ACF + PDT 4h</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIF1A</td>
<td>0.00 ± 0.09</td>
<td>0.58 ± 0.45</td>
<td>0.12 ± 0.31</td>
<td>-0.47 ± 0.42</td>
<td>0.33 ± 0.31</td>
<td>-0.18 ± 0.37</td>
<td>-0.40 ± 0.28</td>
<td>0.41 ± 0.39</td>
<td>0.29 ± 0.21</td>
<td>-0.28 ± 0.27</td>
<td>0.54 ± 0.43</td>
<td>-0.20 ± 0.39</td>
</tr>
<tr>
<td>EDN1</td>
<td>0.00 ± 0.41</td>
<td>-2.00 ± 0.33</td>
<td>-1.14 ± 0.43</td>
<td>1.57 ± 0.28</td>
<td>2.72 ± 1.24</td>
<td>2.62 ± 1.15</td>
<td>0.65 ± 1.25</td>
<td>0.58 ± 0.31</td>
<td>-0.38 ± 0.23</td>
<td>1.15 ± 0.18</td>
<td>3.61 ± 0.25</td>
<td>2.69 ± 0.24</td>
</tr>
<tr>
<td>SERPINE1</td>
<td>0.00 ± 1.18</td>
<td>0.15 ± 0.12</td>
<td>0.00 ± 0.31</td>
<td>-0.65 ± 0.38</td>
<td>0.24 ± 0.36</td>
<td>1.25 ± 0.40</td>
<td>1.29 ± 0.58</td>
<td>1.13 ± 0.37</td>
<td>2.16 ± 0.55</td>
<td>-0.46 ± 0.60</td>
<td>0.77 ± 0.41</td>
<td>0.95 ± 0.57</td>
</tr>
<tr>
<td>VEGF</td>
<td>0.00 ± 0.39</td>
<td>-0.27 ± 0.54</td>
<td>0.07 ± 0.38</td>
<td>0.05 ± 0.18</td>
<td>1.14 ± 0.36</td>
<td>1.25 ± 0.40</td>
<td>1.29 ± 0.58</td>
<td>1.13 ± 0.37</td>
<td>2.16 ± 0.55</td>
<td>-0.46 ± 0.60</td>
<td>0.77 ± 0.41</td>
<td>0.95 ± 0.57</td>
</tr>
<tr>
<td>HK1</td>
<td>0.00 ± 1.04</td>
<td>0.27 ± 0.40</td>
<td>0.00 ± 0.30</td>
<td>-0.35 ± 0.44</td>
<td>-0.65 ± 0.57</td>
<td>0.21 ± 0.61</td>
<td>-0.34 ± 0.57</td>
<td>0.71 ± 0.48</td>
<td>-0.05 ± 0.16</td>
<td>-1.06 ± 0.51</td>
<td>-0.48 ± 0.19</td>
<td>-0.40 ± 0.21</td>
</tr>
<tr>
<td>LDHA</td>
<td>0.00 ± 0.38</td>
<td>-0.20 ± 0.06</td>
<td>0.18 ± 0.36</td>
<td>-0.80 ± 0.71</td>
<td>-0.18 ± 0.53</td>
<td>0.40 ± 0.40</td>
<td>-0.47 ± 0.16</td>
<td>1.03 ± 0.08</td>
<td>0.02 ± 0.88</td>
<td>-0.68 ± 0.34</td>
<td>0.12 ± 0.59</td>
<td>0.89 ± 0.21</td>
</tr>
<tr>
<td>PDHA</td>
<td>0.00 ± 0.42</td>
<td>0.22 ± 0.80</td>
<td>0.40 ± 0.46</td>
<td>0.74 ± 0.47</td>
<td>1.30 ± 0.81</td>
<td>0.65 ± 0.00</td>
<td>0.49 ± 0.22</td>
<td>0.43 ± 0.18</td>
<td>0.50 ± 0.31</td>
<td>0.31 ± 0.18</td>
<td>0.15 ± 0.07</td>
<td>0.79 ± 0.25</td>
</tr>
<tr>
<td>PGK1</td>
<td>0.00 ± 0.39</td>
<td>0.13 ± 0.30</td>
<td>0.19 ± 0.85</td>
<td>0.39 ± 0.21</td>
<td>0.15 ± 0.43</td>
<td>0.03 ± 0.04</td>
<td>1.08 ± 0.30</td>
<td>1.17 ± 0.12</td>
<td>0.13 ± 0.78</td>
<td>1.17 ± 0.98</td>
<td>1.11 ± 0.82</td>
<td>0.79 ± 0.80</td>
</tr>
<tr>
<td>PKM2</td>
<td>0.00 ± 0.20</td>
<td>-0.21 ± 0.40</td>
<td>0.00 ± 0.42</td>
<td>-0.24 ± 0.37</td>
<td>0.09 ± 0.31</td>
<td>0.01 ± 0.02</td>
<td>-0.43 ± 0.44</td>
<td>0.65 ± 0.45</td>
<td>0.07 ± 0.28</td>
<td>0.41 ± 0.15</td>
<td>-0.27 ± 0.52</td>
<td>-0.07 ± 0.35</td>
</tr>
<tr>
<td>BCL2</td>
<td>0.00 ± 0.21</td>
<td>-0.49 ± 0.21</td>
<td>0.17 ± 0.14</td>
<td>-0.16 ± 0.57</td>
<td>-0.34 ± 0.81</td>
<td>1.74 ± 0.04</td>
<td>0.48 ± 0.36</td>
<td>0.54 ± 0.47</td>
<td>-0.76 ± 0.12</td>
<td>-1.14 ± 0.80</td>
<td>-0.79 ± 0.15</td>
<td>-0.08 ± 0.83</td>
</tr>
<tr>
<td>BECN1</td>
<td>0.00 ± 0.30</td>
<td>-0.92 ± 0.07</td>
<td>0.22 ± 0.17</td>
<td>1.04 ± 0.28</td>
<td>1.54 ± 0.31</td>
<td>2.07 ± 0.53</td>
<td>0.18 ± 0.36</td>
<td>0.30 ± 0.37</td>
<td>0.95 ± 0.18</td>
<td>-0.23 ± 0.40</td>
<td>0.84 ± 0.29</td>
<td>0.60 ± 0.23</td>
</tr>
<tr>
<td>BIRC5</td>
<td>0.00 ± 0.42</td>
<td>-0.72 ± 0.65</td>
<td>0.08 ± 0.36</td>
<td>0.62 ± 0.21</td>
<td>1.87 ± 0.14</td>
<td>1.08 ± 0.80</td>
<td>0.19 ± 0.77</td>
<td>1.12 ± 0.58</td>
<td>0.35 ± 0.22</td>
<td>0.74 ± 0.18</td>
<td>0.45 ± 0.55</td>
<td>0.84 ± 0.46</td>
</tr>
<tr>
<td>HMBOX1</td>
<td>0.00 ± 0.16</td>
<td>1.20 ± 0.45</td>
<td>0.10 ± 0.16</td>
<td>0.94 ± 0.51</td>
<td>2.10 ± 1.35</td>
<td>1.05 ± 0.60</td>
<td>0.62 ± 0.40</td>
<td>0.63 ± 0.11</td>
<td>2.04 ± 1.10</td>
<td>0.73 ± 0.41</td>
<td>1.04 ± 0.23</td>
<td>0.90 ± 0.06</td>
</tr>
<tr>
<td>HSPA5</td>
<td>0.00 ± 0.21</td>
<td>-0.64 ± 0.49</td>
<td>0.27 ± 0.12</td>
<td>-0.33 ± 0.81</td>
<td>-1.33 ± 0.76</td>
<td>-1.54 ± 0.44</td>
<td>-1.11 ± 1.04</td>
<td>0.08 ± 0.22</td>
<td>0.10 ± 0.13</td>
<td>-3.35 ± 0.12</td>
<td>-2.09 ± 0.52</td>
<td>-1.08 ± 0.24</td>
</tr>
<tr>
<td>PTGS2</td>
<td>0.00 ± 0.48</td>
<td>0.59 ± 0.33</td>
<td>1.21 ± 0.10</td>
<td>1.74 ± 0.11</td>
<td>2.68 ± 0.92</td>
<td>-1.07 ± 0.20</td>
<td>1.17 ± 0.00</td>
<td>0.24 ± 0.97</td>
<td>4.13 ± 0.33</td>
<td>-0.53 ± 0.92</td>
<td>3.14 ± 0.60</td>
<td>2.72 ± 0.24</td>
</tr>
</tbody>
</table>

**Table 2.** Overview of the mean, Log2 transformed fold-changes in mRNA levels and standard deviations.
production of lactate, the production of lactate was quantified in the cell culture medium 24 hours after ACF and PDT treatment (Fig. 4H). Lactate excretion levels were substantially increased under hypoxic conditions in all treatment groups compared to normoxic cells, validating our hypoxic incubation model. However, no further intergroup differences were observed in this cell line with respect to lactate production. Neither ACF nor PDT therefore induced notable metabolic catastrophe in cells.

Figure 6. Response to ACF after prolonged exposure. (A-D) Sk-Cha1 cells were incubated with ACF for either (A, B) 24 hours or (C, D) 48 hours, after which the cell cycle profile was analyzed with flow cytometry using a propidium iodide staining (n = 3 per group). (E) Flow cytometric analysis of Sk-Cha1 cells that were incubated with ACF for either 24 hours (in grey) and 48 hours (in white) after which the fraction of apoptotic (Annexin V-positive) and (F) necrotic (TO-PRO-3-positive) cells was determined (n = 3 per group). (G, H) Sk-Cha1 cells were exposed to ACF for (G) 24 hours and (H) 48 hours and intracellular DCF fluorescence was determined as a measure for ROS production. (I-P) Analysis of DNA damage after control (CTRL) or ACF treatment. Sk-Cha1 cells received ACF or CTRL treatment for (I-L) 24 hours or (M-P) 48 hours, and were subsequently stained with DAPI (nuclei, blue) and phospho-H2AX (DNA double-strand breaks, red).
3.5 ACF interferes with the regulation of HIF-1-induced target genes

To study whether pre-treatment with ACF influences post-PDT HIF-1α signaling, Sk-Cha1 cells were incubated with ACF and subsequently treated with PDT and maintained under hypoxic conditions. HIF-1 downstream targets were clustered in angiogenesis-, glycolysis-, and survival-associated genes and analyzed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) at different time points after PDT (Fig. 5). Moreover, additional HIF-1 target genes were included in the ACF-related transcriptomic analysis. PDT induced the expression of VEGF, HMOX1, and PTGS2, corroborating the data in Fig. 2C. ACF reduced the degree of PTGS2 upregulation (only in the 0-h and 2-h group) and VEGF transcription post-PDT. Conversely, EDN1 was downregulated by hypoxia and PDT but upregulated by ACF. In addition, SERPINE1 was highly induced upon ACF treatment - an effect that was also observed after PDT in the presence of ACF. Altogether, these findings indicate that ACF by itself and in combination with PDT modulates several important HIF-1-induced transcriptional targets. However, the direction of the regulation is not always consistent within one functional class.

3.6 Long-term exposure to ACF causes cell cycle arrest and apoptosis

Although ACF is generally considered a specific HIF-1α/HIF-1β dimerization inhibitor, Hassan et al. have reported that ACF may also act as a dual topoisomerase I/II inhibitor. Topoisomerase I/II inhibition is associated with cell cycle arrest and consequent apoptosis as a result of DNA double-strand breaks (reviewed in 35, 56). In the acute phase after PDT, DNA double-strand breaks were not observed (Fig. 4I-P) but apoptotic signaling was pronounced, particularly in the ACF + PDT and hypoxia groups (Fig. 4F and G). To investigate the potential topoisomerase I/II inhibitory effects, Sk-Cha1 cells were exposed to ACF for longer time frames (24 and 48 hours) under normoxic conditions, after which the cell cycle profile was analyzed using propidium iodide staining (Fig. 6A-D). As shown in Fig. 6B and 6D, ACF led to an increased fraction of cells in both the S- and G2/M-phase after 24 and 48 hours of incubation. The most significant effect of ACF was characterized by cell cycle arrest in the S-phase after 48 hours of incubation. Furthermore, ACF treatment was associated with increased apoptosis, but not necrosis, after 24 and 48 hours (Fig. 6E, F), which concurred with elevated ROS production in cells (Fig. 6G, H). Finally, incubation of Sk-Cha1 cells with ACF for 24 or 48 hours led to the formation of DNA double-strand breaks (Fig. 6I-P), although not in a concentration-dependent manner.

4. Discussion

Perihilar cholangiocarcinoma is a relatively rare cancer that is non-resectable in 70-80% of patients at the time of diagnosis. Although PDT is not curative in these patients, the treatment does prolong the median survival of 6-9 months (stenting) to 21 months post-diagnosis (stenting + PDT). Driven by these promising results, novel avenues are being explored to enhance PDT efficacy in these refractory and rather lethal cancers. PDT is associated with microvasculature shutdown and consequent HIF-1 signaling that may contribute to therapeutic recalcitrance. Therefore, this study was conducted to investigate the expression of HIF-1-induced proteins in perihilar cholangiocarcinomas to gauge whether inhibition of HIF-1 may be exploited as a therapeutic target in the context of PDT. Histological analysis revealed that human perihilar cholangiocarcinomas overexpress VEGF homogeneously and GLUT-1 heterogeneously and are replete with neoangiogenic vessels in the desmoplastic tissue, suggesting that HIF-1 is constitutively active in these tumors. Second, PDT of Sk-Cha1 cells with ZnPC-encapsulating liposomes caused HIF-1α stabilization and transcriptional upregulation of downstream targets of HIF-1. Third, ACF was taken up by Sk-Cha1 cells, especially during hypoxia, and translocated to the nucleus upon hypoxia and PDT. Lastly, ACF pretreatment was associated with S-phase cell cycle arrest and apoptosis and enhanced PDT efficacy, likely via inhibition of HIF-1 inhibition and topoisomerase I/II.
HIF-1α stabilization after PDT has been observed in various experimental settings. Ferrario et al. revealed that porfimer sodium-PDT resulted in HIF-1α stabilization in murine Kaposi’s sarcoma 30. PDT also upregulated the HIF-1-associated targets VEGF and COX-2 30. In mouse mammary carcinoma (BA) xenografts 31, porfimer-PDT led to an increase in HIF-1α, BIRC5, and VEGF protein levels. Lastly, murine mammary carcinoma (EMT-6) cells that were treated with porfimer sodium-PDT exhibited HIF-1α stabilization and its consequent translocation to the nucleus 28. In line with these findings, our study demonstrated that HIF-1α was stabilized in Sk-Cha1 cells after incubation in a hypoxic chamber (to mimic vascular shutdown) and after PDT. PDT also led to the differential regulation of HIF-1-regulated genes, including VEGF, PTGS2, SERPINE1, HMOX1, and BIRC5. Consistent with these results, it was recently demonstrated that Sk-Cha1 cells subjected to sublethal PDT with neutral ZnPC-encapsulating liposomes significantly upregulated HIF-1-associated genes 90 minutes post-PDT 44. Altogether, these findings attest that HIF-1α is activated following PDT and that this transcription factor constitutes an important therapeutic target, particularly in light of the fact that HIF-1 regulates biological processes that are important in PDT, such as glycolysis, angiogenesis, and survival 10.

The combinatorial use of HIF-1 inhibitors with PDT is a relatively new concept. For instance, Chen et al. used HIF-1α siRNAs in combination with Photosan-PDT in a head-and-neck cancer mouse model, which resulted in regression of tumor volume by ~40% within 10 days 58. Besides HIF-1 inhibition, its downstream target VEGF has been inhibited in various studies 32, 59, 60, which generally led to improved therapeutic efficacy. Although downstream targets of HIF-1 may be inhibited, from a pharmacology point of view it would be more attractive to inhibit HIF-1 itself, inasmuch as all the downstream targets are blocked concomitantly. As such, the HIF-1α/HIF-1β dimerization inhibitor ACF was evaluated for its adjuvant potential in Sk-Cha1 cells. ACF specifically binds the PER-ARNT-SIM (PAS) domain of HIF-1α and HIF-2α, which prevents the dimerization of HIF-1, thereby deterring its activation 54. It was observed that ACF was taken up by Sk-Cha1 cells and translocated to the nucleus after hypoxia and/or PDT, presumably due to its binding to HIF-1α and HIF-2α. Moreover, ACF remained stable during the application of intense (laser) light exposure as well as during conditions of oxidative stress, suggesting that ACF will be able to inhibit HIF-1 after PDT and consequent vascular shutdown. The IC50 value of ACF in Sk-Cha1 cells was 29 μM during normoxia, which is in the range that has been observed for other cell lines 61. Strese et al. found that human leukemic monocyte lymphoma (U937) were most susceptible to ACF, as demonstrated by an IC50 value of 4.6 μM, whereas human breast cancer (MCF-7) cells exhibited an IC50 value of 61 μM 61. Pretreatment of Sk-Cha1 cells with ACF significantly improved therapeutic efficacy, which was at least partially mediated by the increase in caspase 3/7 levels (apoptosis).

In addition to HIF-1 inhibition, ACF has also been shown to act as a dual topoisomerase I/II inhibitor 34. Of note, topoisomerase inhibitors (e.g., topotecan 62) may also repress gene transcription, but to what extent ACF is able to inhibit HIF-1-mediated signaling via this mechanism is currently elusive. Topoisomerase class I and II inhibitors cleave either one or both strands of DNA, respectively. Both topoisomerase I and II inhibitors may induce the formation of DNA double-strand breaks, inasmuch as the single-strand break that is induced by topoisomerase I inhibitors may turn into a double-strand break when the topoisomerase I cleavable complex collides with the replication fork 63. This type of DNA damage may culminate in cell cycle arrest via tumor protein 53 (p53)-mediated p21WAF1/CIP1 induction, cellular senescence, and both p53-dependent and p53-independent apoptosis 35, 56, 63, 64. To determine whether the observed cell death could (in part) be explained by topoisomerase I/II inhibition, Sk-Cha1 cells were incubated with ACF for 24 and 48 hours (i.e., a full cell cycle requires 48 hours 36). It should be noted that, although Sk-Cha1 cells have a mutation (at codon 282) in the DNA binding domain of p53 65, their p53 is still functional. ACF incubation led to cell cycle arrest in both the S-phase and the G2/M-phase and was associated with an increased percentage of apoptotic cells. Sk-Cha1 cells also exhibited DNA double-strand breaks as a result of ACF incubation. Collectively, these findings support the notion that ACF exhibits topoisomerase I/II inhibition activity that may contribute to greater therapeutic efficacy.

An interesting finding of this study is the upregulation of SERPINE1 after ACF treatment.
SERPINE1 is a downstream target of both HIF-1 and p53 and its protein product plasminogen activator inhibitor 1 (PAI1) is known to exhibit pleiotropic effects. PAI1 is involved in the inhibition of extracellular matrix remodeling, but it also has anti-apoptotic and pro-proliferative capacities and is involved in angiogenesis. This has been exemplified by Devy et al., who demonstrated that cultured mouse aortic rings from PAI1-deficient mice, which were stimulated with PAI1, exhibited a dose-dependent angiogenic response. Whereas low-dose levels of PAI1 were associated with increased angiogenesis, high-dose levels of PAI1 inhibited microvessel formation. To what extent p53 is responsible for SERPINE1 induction after ACF treatment is currently elusive, as are the consequences of PAI1 induction in the context of PDT.

As stated earlier, the use of inhibitors of specific survival pathways with PDT is a relatively novel strategy. Several studies have indicated that inhibition of survival pathways in conjunction with PDT may be an attractive means to enhance PDT efficacy (reviewed in 10). Consistent with these results, the present findings also encourage the use of small molecule inhibitors (e.g., HIF-1 inhibitors) of survival pathways together with PDT. These small molecule inhibitors can be co-encapsulated with a photosensitizer into a single drug delivery system, such as liposomes, in order to improve treatment outcome.

5. Conclusions.

HIF-1 is overexpressed in a variety of solid cancers and is often associated with therapeutic recalcitrance, inasmuch as it stimulates glycolysis, angiogenesis, and survival. This study demonstrated that HIF-1 inhibition via ACF may be an attractive method to potentiate PDT efficacy in perihilar cholangiocarcinoma. Interestingly, not only HIF-1 inhibition, but also topoisomerase I/II inhibition by ACF may further contribute to increased PDT efficacy. In vivo studies as addressed in 70 are necessary to validate the potential of ACF in combination with PDT.

Acknowledgements

This work was financed with grants from the Phospholipid Research Center in Heidelberg, the Dutch Anticancer Foundation in Amsterdam (Stichting Nationaal Fonds Tegen Kanker), and the Nijbaker Morra Foundation. The Sk-Cha1 cells were a kind gift from Alexander Knuth and Claudia Matter from the University Hospital Zurich, Switzerland. The authors are grateful to Marcel Dirkes and Adrie Maas for input regarding the hypoxic incubator, and Ron Hoebe and Daisy Picavet for the technical assistance with confocal microscopy.

References

17. Salceda, S.; Caro, J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic con-


the European Society for Photobiology 2007, 6, 1275-83.


67. Gramling, M. W.; Church, F. C. Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thrombosis Research 2010, 125, 377-381.